(Q34594355)

3 August 2017

Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib (English)

1 reference

3 August 2017

1 reference

Abdullah Hacihanefioglu

series ordinal

1

1 reference

3 August 2017

Pinar Tarkun

series ordinal

2

1 reference

3 August 2017

Emel Gonullu

series ordinal

3

1 reference

3 August 2017

17 July 2008

1 reference

International Journal of Hematology

3 August 2017

1 reference

3 August 2017

88

1 reference

3 August 2017

2

1 reference

3 August 2017

219-222

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-008-0139-7

3 August 2017

0 references

cites work

Protein degradation and protection against misfolded or damaged proteins

1 reference

12 December 2020

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

1 reference

12 December 2020

The ubiquitin-proteasome system: focus on the heart.

1 reference

12 December 2020

Proteasome inhibition as novel treatment strategy in leukaemia

1 reference

12 December 2020

Unexpected cardiotoxicity in haematological bortezomib treated patients

1 reference

12 December 2020

Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma

1 reference

12 December 2020

New drugs for myeloma

1 reference

12 December 2020

The ubiquitin-proteasome system in cardiac physiology and pathology

1 reference

12 December 2020

Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB.

1 reference

12 December 2020

The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended

1 reference

12 December 2020

The proteasome: a novel target for cancer chemotherapy

1 reference

12 December 2020

Into the heart: the emerging role of the ubiquitin-proteasome system.

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report

1 reference

12 December 2020

Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells

1 reference

12 December 2020

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

1 reference

12 December 2020

10.1007/S12185-008-0139-7

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1018021712

0 references

Fatcat ID

release_25jeejbtljdzjjgalaadh4ef5e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/25jeejbtljdzjjgalaadh4ef5e

24 November 2022

mapped directly with Wikidata item

1 reference